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Chronic active Epstein-Barr virus infection (CAEBV) is a severe illness with unusual EBV
activation that persists for years, and its pathogenesis is largely unknown. After the creation
of an accurate and reproducible polymerase chain reaction system to quantify EBV DNA,
virus loads in peripheral blood lymphocytes (PBL) were determined in 54 children: 15 with
CAEBV, 16 with infectious mononucleosis (IM), and 23 healthy children. Children with
CAEBV and those with IM had high virus loads. Lower loads were detected in 47% of
seropositive healthy donors. There were two distinct differences between children with CAEBV
and those with IM: The former had greater viral replication (103–107 copies/ PBL)52.5 3 10
than those with IM, and viral replication declined in children with IM whereas active repli-
cation persisted for years in subjects with CAEBV. Persisting high virus loads are a possible
diagnostic criterion for CAEBV. EBV loads may enable classification and prognosis of EBV
infections.
Epstein-Barr virus (EBV) is a causative agent of infectious
mononucleosis (IM) [1] and of chronic active EBV infection
(CAEBV). CAEBV is a severe illness with unusual EBV acti-
vation that may be fatal with multiple organ failure, and it is
associated with malignant lymphoma without prior immuno-
suppression [2, 3]. The clinical symptoms of CAEBV and the
serologic abnormalities corresponding to active EBV replica-
tion, such as markedly elevated anti–EA-DR antibody and ab-
sence of Epstein-Barr nuclear antigen (EBNA) antibody, persist
for months to years. EBV replicates in NK [4], T [5], and B
cells.
Once the infection is established, EBV usually resides in B
lymphocytes for the host’s lifetime without causing any clinical
symptoms (designated as a latent infection). Therefore, not only
the detection but also the quantification of EBV in affected
tissues is essential to investigate EBV disease.
To clarify the status of EBV replication in persons with
CAEBV, we used semiquantitative DNA polymerase chain re-
action (PCR) to evaluate and compare virus loads in peripheral
blood lymphocytes (PBL) in 3 groups of children: one with
CAEBV, one with IM, and healthy controls. Our detection
system was considered accurate and reliable for the quantifi-
cation of EBV because we amplified a single-copy region of
EBV. Most previous studies targeted the BamHI-W region for
which tandem repeat reiteration frequency is inconstant. We
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believe this study is the first and largest scaled study of virus
loads in PBL of children with CAEBV.
Materials and Methods
Patients and controls. We examined 16 children with IM (11
boys, 5 girls; ages, 0–8 years), 15 with CAEBV (11 boys, 4 girls;
ages, 4–19 years), 19 immunocompetent EBV-seropositive healthy
persons (10 boys, 9 girls; ages, 1–19 years), and 4 seronegative
healthy children (3 boys, 1 girl; ages, 1–10 years). All subjects with
IM presented with typical clinical manifestations (e.g., fever, ton-
sillitis, lymphadenopathy, hepatosplenomegaly, liver dysfunction,
and atypical lymphocytosis). The diagnosis of IM was made on
the basis of serologic findings of IgM antibody to viral capsid
antigen (VCA) or seroconversion of VCA IgG and/or EA and
negative EBNA antibody [6]. Twenty-two blood samples were col-
lected from 16 children with IM 8 days to 8 months after disease
onset (the initial symptom was fever in all patients). CAEBV was
diagnosed by Rickinson’s criteria [7]. Children with CAEBV had
intermittent or persistent fever for 16 months, with hepatosplen-
omegaly, lymphadenopathy, and/or skin rash. The laboratory find-
ings showed elevated transaminase levels, anemia, thrombocyto-
penia, and/or polyclonal hypergammaglobulinemia. Serologic
examination revealed marked elevation of antibody titers to VCA
and EA. Human immunodeficiency virus infection and rheumatic
diseases were excluded. No subjects had undergone transplantation
or had anticancer therapy.
Samples. Heparinized 2-mL peripheral blood samples were
collected. PBL were isolated by ficoll-hypaque and lysed with 0.15
mg/mL proteinase K (Boehringer-Mannheim, Indianapolis); DNA
was extracted with phenol-chloroform-ethanol precipitation. The
extracted DNA was quantified by spectrophotometer, adjusted to
0.25 mg/mL DNA, and used as the PCR templates.
PCR sensitivity. EBV DNA were from three sources: Raji,
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Figure 1. EBV DNA in peripheral blood lymphocytes (PBL) at
diagnosis in healthy controls (4 EBV-seronegative, 19 -seropositive), 16
children with infectious mononucleosis (IM), and 15 patients with
CAEBV infection. In 9 of 19 healthy EBV-seropositive children, EBV
DNA was detectable (100–1000 copies/ PBL). Larger quan-52.5 3 10
tities of EBV genome were detected in PBL from patients with EBV
disease.
containing 50 copies of EBV per cell [8]; Akata, containing 20
copies per cell; and cloned BamHI-L fragments, which were mixed
with DNA from cord blood cells and used as a positive standard.
To determine the sensitivity of the PCR system, serial 10-fold di-
lutions (100–104 copies of EBV) of the DNA extracted were sub-
jected to PCR.
PCR. A nested double PCR was designed to amplify the con-
served region encoding gp220 (within the BamHI-L fragment) [9].
The outer primer pair amplifies a 302-bp fragment, by using the
oligonucleotides 5′-GCGAACTGGTGGACACATGA and 5′-AA-
GTCCACAGGCAAATGCCA, corresponding to positions 2870–
3171 of B95-8 (GenBank M10593). The inner pair amplifies a 239-
bp fragment [10]. The PCR was performed in a 50-mL reaction
containing 50 mM KCl, 1.5 mM MgCl2, 200 mM dNTP, 0.5 mM
of each primer, 2.5 U of Taq DNA polymerase (Boehringer-Mann-
heim), and 4 mL of sample DNA. The products amplified were run
on 2% agarose and stained with ethidium bromide, and Southern
blotting was used to confirm the specificity using the BamHI-L
fragment as a probe [10]. Each PCR reaction was done in triplicate
and included the negative control to exclude cross-contamination.
To confirm the specificity of the PCR, DNA was analyzed from
herpes simplex virus types 1 and 2, varicella-zoster virus, human
cytomegalovirus, and human herpesviruses-6 and -7. No specific
amplification was noted.
Quantification of EBV genome. The quantity of EBV DNA in
PBL was determined by limiting dilution experiments. Serial 10-
fold dilutions (1–1026 mg) of genomic DNA extracted from each
sample DNA was subjected to the nested PCR as described above,
and the minimal limit for the positive result was converted into
the virus load (copies/ cells).52.5 3 10
Results
The sensitivity of the PCR system was carefully determined
by 10-fold dilutions of the three sources of EBV DNA: Raji
and Akata, both containing constant copy numbers of EBV
DNA per cell, and the cloned BamHI-L fragment. Raji contains
50 copies of EBV genome per cell [8], and 1 mg of genomic
DNA from Raji cells equals that extracted from cells:52.5 3 10
hence, copies of EBV DNA. The DNA from Raji71.25 3 10
was diluted appropriately, and DNA containing 10n copies (se-
rial dilutions of 100–104 copies of the virus) was subjected to
amplification. The minimal limit for a positive PCR result was
examined. Repeated examinations revealed that the sensitivity
was 100 copies per reaction with reproducibility. Results were
the same using Akata DNA and with the dilution experiment
using 10n copies of BamHI-L fragments mixed with 105 mg, 102
mg, and no cord blood cell DNA.
All PBL from subjects with IM and CAEBV were positive
for the EBV genome. Nine (47%) of 19 samples from EBV-
seropositive healthy persons were positive. All PBL from sero-
negative persons were negative.
EBV DNA in PBL was quantified and compared for EBV-
seropositive healthy controls, children with IM, and children
with CAEBV (figure 1). In healthy EBV-seropositive children,
the virus loads were 100–1000 copies per PBL. In52.5 3 10
PBL from children with IM, the lowest limits for positive
PCR results ranged from 100 mg ( PBL) to 1023 mg52.5 3 10
( /PBL) of genomic DNA, indicating that the virus load22.5 3 10
was 100–100,000 copies/ PBL. Three blood samples52.5 3 10
collected within a month after the disease onset harbored higher
loads (1000–100,000 copies/ PBL). The PBL collected52.5 3 10
11 month after onset of IM tended to contain decreased quan-
tities of the virus. We followed the virus loads in 4 IM patients
(figure 2A). In all 4, the virus loads decreased during the clinical
course but were higher (100–10,000 copies/ PBL) than52.5 3 10
in the seropositive healthy hosts.
The PBL from children with CAEBV had more EBV DNA
than did samples from children with IM. Four CAEBV patients
were followed for 16 months (figure 2B illustrates the findings
for 2 patients). Two other patients had unchanged virus loads
over 2–3 years (105 and 106 copies/ PBL, respectively).52.5 3 10
All of these patients had persistently high virus loads, unlike
the findings with IM. When we examined the relationship be-
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Figure 2. A, EBV loads and times from disease onset to blood collection. 12 blood samples collected within 1 month after onset of infectious
mononucleosis (IM) harbored large quantities of EBV (1000–100,000 copies/ cells). Peripheral blood lymphocytes (PBL) collected >152.5 3 10
month after onset of IM tended to less virus. 4 IM patients were followed to test virus loads. In all 4, EBV DNA declined during clinical course
of disease. B, Temporal change of EBV loads in PBL of 2 patients (UT, YK) with CAEBV. Large quantities of EBV DNA were consistently
detected in PBL.
tween the clinical manifestations and the EBV loads, only fever
was correlated with the virus load. There was no correlation
with hepatosplenomegaly, lymphadenopathy, exanthema, mos-
quito allergy, liver dysfunction, anemia, thrombocytopenia, or
serum antibody titers against VCA, EA-DR, and EBNA.
Discussion
The PCR quantifying EBV DNA demonstrated that the PBL
from children with CAEBV or IM had high virus loads, in-
dicating active EBV replication in the lymphocytes. The viral
replication was considered more active in CAEBV than in IM;
in the IM group the replication gradually declined, whereas
active replication persisted for years in the CAEBV patients.
Our PCR system amplifies EBV-specific sequences encoding
gp220, which is a single copy gene in a virus, whereas the
previous studies targeted the internal repeating long located in
the BamHI-W region. Since in polyclonal EBV proliferation
the repeating number of this region is inconstant, our system
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is considered more accurate for quantifying EBV, though less
sensitive for detection. The defect of low sensitivity was over-
come by use of the nested PCR. The sensitivity was 100 copies
per reaction, compared with 10 copies in the previous report
[11]. We quantified EBV genomes in PBL by the serial dilution
of extracted DNA. Our system quantifying EBV DNA by serial
dilutions of extracted DNA was shown to be reproducible and
reliable.
The PBL collected from children with IM and with CAEBV
harbored larger quantities of the EBV genome than did PBL
from healthy seropositive controls. Of the latter, 47% had de-
tectable EBV DNA (100–1000/ PBL). EBV in 2 sub-52.5 3 10
jects was detected at higher levels than in the previous studies
(1–50/106 PBL) [11]. Since we studied children, the shorter pe-
riods after primary infection may contribute to the higher EBV
loads than seen in previous studies of adults, reminding us that,
especially in children, positive PCR results include asympto-
matic latent EBV infection.
The children with IM had large quantities of EBV. EBV loads
peaked within a month after onset (1000–100,000 copies/
PBL) and then gradually decreased but remained high52.5 3 10
several months (<8) after onset, compared with levels in healthy
controls. Even when the clinical manifestations disappeared,
relatively high levels of EBV replication continued in the PBL.
The patients with CAEBV had persistently large quantities
of EBV, suggesting that chronic unregulated active replication
of EBV in PBL results in severe illness with a poor prognosis.
The factors and mechanisms leading to the surprisingly active
viral replication remain unclear. Various heterogeneous defi-
ciencies in host defense systems of both humoral and cellular
immunity have been described [2, 3] and might allow active
viral replication. High virus load in PBL (1300,000 EBV/105
PBL) has been shown in EBV-associated postransplant lym-
phoproliferative disease (PTLD), a complication after trans-
plantations [12, 13], although the virus loads decreased within
a year in parallel with the recovery from immunosuppression.
A quantitative difference in circulating EBV load was correlated
with EBNA antibody level in PTLD [12] but not in CAEBV.
Therefore, the behavior of EBV in PTLD was considered to
be both similar to and different from that in CAEBV. In view
of the clinical manifestations, CAEBV seems similar to X-
linked lymphoproliferative (XLP) syndrome [14], for which the
responsible gene was recently identified. However, unlike XLP
syndrome, CAEBV is not a hereditary disease, and females can
be affected. Further immunologic analysis of CAEBV is nec-
essary to clarify predisposing factors for the viral activation.
Acyclovir, interferon-a, and interleukin-2 have been used to
treat CAEBV—with unsatisfactory results [2, 3]. Our results
indicate that cytotoxic drugs that induce immunosuppression
and enhance the viral activation should be chosen carefully,
although the clinical features are similar to those of hematologic
malignancies. Persisting high EBV loads in PBL are a possible
diagnostic criterion for CAEBV and may be useful for moni-
toring the disease activity, for classifying the disease, and for
predicting the prognosis.
Acknowledgments
We thank George Klein (Microbiology and Tumorbiology Center,
Karolinska Institute, Stockholm) for reviewing the manuscript and
Sachi Takemoto and Ai Kitamura for skillful technical assistance.
References
1. Straus SE, Dohen JI, Tosato G, Meiser J. NIH conference. Epstein-Barr
virus infections: biology, pathogenesis, and management. Ann Intern Med
1993;118:45–58.
2. Okano M, Matsumoto S, Osato T, Sakiyama Y, Thiele GM, Purtilo DT.
Severe chronic active EBV infection syndrome. Clin Microbiol Rev 1991;
4:129–35.
3. Ishihara S, Okada S, Wakiguchi H, Kurashige T, Morishima T, Kawa-Ha
K. Chronic active Epstein-Barr virus infection in children in Japan. Acta
Paediatr 1995;84:1271–5.
4. Kawa-Ha K, Ishihara S, Ninomiya T, et al. CD3-negative lymphoproiferative
disease of granular lymphocytes containing Epstein-Barr viral DNA. J
Clin Invest 1989;84:51–5.
5. Kikuta H, Taguchi Y, Tomizawa K, et al. Epstein-Barr virus genome–positive
T lymphocytes in a boy with chronic active EBV infection associated with
Kawasaki-like disease. Nature 1988;333:455–7.
6. Sumaya CV, Ench Y. Epstein-Barr virus infectious mononucleosis in children.
I. Clinical and general laboratory findings. Pediatrics 1985;75:1003–10.
7. Rickinson AB. Chronic, symptomatic EBV infections. Immunol Today
1986;7:13–4.
8. Gussander E, Adams A. Electron microscopic evidence for replication of
circular Epstein-Barr virus genomes in latently infected Raji cells. J Virol
1984;52:549–56.
9. Beisel C, Tanner J, Matsuo T, Thorley-Lawson D, Kezdy F, Kieff E. Two
outer envelope glycoproteins of Epstein-Barr virus are encoded by the
same gene. J Virol 1985;54:665–74.
10. Telenti A, Marshall WF, Smith TF. Detection of Epstein-Barr virus by poly-
merase chain reaction. J Clin Microbiol 1990;28:2187–90.
11. Wagner HJ, Bein G, Bitsch A, Kirchner H. Detection and quantification of
latently infected B lymphocytes in Epstein-Barr virus–seropositive,healthy
individuals by polymerase chain reaction. J Clin Microbiol 1992;30:
2826–9.
12. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Ep-
stein-Barr virus (EBV)–infected lymphocytes and decreased EBV nuclear
antigen antibody responses are associated with the development of post-
transplant lymphoproliferative disease in solid-organ transplant recipients.
Blood 1994;84:972–84.
13. Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein-Barr
virus (EBV) polymerase chain reaction for the determination of patients
at risk for EBV-induced lymphoproliferative disease after stem cell trans-
plantation. Blood 1998;91:3654–61.
14. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease
gene product SAP regulates signals induced through the co-receptor
SLAM. Nature 1998;395:462–9.
